Study shows the power of electroencephalography and machine learning to help predict response to psychotherapy (or lack thereof) in patients with PTSD

By SharpBrains | May 2, 2023

A fas­ci­nat­ing study just pub­lished in Nature Men­tal Health aimed at help­ing pre­dict the out­comes of psy­chother­a­py for patients with Post-Trau­­mat­ic Stress Dis­or­der (PTSD) using Machine Learn­ing (ML) and elec­troen­cephalog­ra­phy (EEG) data. PTSD is a men­tal health con­di­tion trig­gered by expe­ri­enc­ing or wit­ness­ing a trau­mat­ic event; two evi­­dence-based treatments–Prolonged Expo­sure (PE) and Cog­ni­tive Pro­cess­ing Ther­a­py (CPT)–are…

Read More

BrainHealth Week starts today! Plus: dancing, personalized mental health, brain stimulation and more

By SharpBrains | February 20, 2023

Wel­come to a new edi­tion of Sharp­Brains e‑newsletter, annouc­ing the kick-off of Brain­Health Week and fea­tur­ing some stim­u­lat­ing resources and teasers. #1. Brain­Health Week (Feb­ru­ary 20–24th) starts today: Explore many fun events includ­ing a dai­ly text chal­lenge, a talk with the always great Dr. Tom Insel, and more! #2. With­out Brain Health, you do not have…

Read More

Alto Neuroscience raises $60M (equity + credit) to help fix the “trial and error” approach to psychiatric medication

By SharpBrains | January 31, 2023

Alto Neu­ro­science bags $25M for four Phase II drugs (End­points News): Anoth­er $25 mil­lion is flow­ing the way of a Cal­i­for­nia biotech attempt­ing to fix the “tri­al and error” sys­tem in neu­ro­science drug R&D. Alto Neu­ro­science picked up the cap­i­tal from Alpha Wave Ven­tures via an exten­sion to its Series B, bring­ing total equi­ty raised…

Read More

Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

By SharpBrains | November 7, 2022

Alto Neu­ro­science Rais­es $35M Series B Financ­ing (Fins­Mes): Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­try, rais­es $35M Series B Financ­ing … The com­pa­ny intends to use the funds to advance lead can­di­dates into Phase 2b stud­ies in major depres­sive dis­or­der … Pro­ceeds from the financ­ing will also be used…

Read More